Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Status:
Not yet recruiting
Trial end date:
2024-12-23
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label study of the safety, pharmacokinetics (PK), pharmacodynamics,
and anti-tumor activity of single-agent BLU-451. All subjects will receive BLU-451 as a
single agent administered once daily (QD) or twice daily (BID) on a 21-day treatment cycle.